TScan Therapeutics, Inc.
Nasdaq · Healthcare · Biological Products, (No Diagnostic Substances) · Waltham, MA
TCRX chart
What traders are saying about $TCRX
Latest postsTScan Therapeutics, Inc. news
- TScan Therapeutics Proposes Reverse Stock Split, Seeks Shareholder Approval
Kalkine Media ·
- Form DEF 14A Tscan Therapeutics Inc For: 26 October By Investing.com
Investing.com South Africa ·
- Ionis’ rare neurology drug approved; Pfizer inks an ADC deal
biopharmadive.com ·
- TScan Therapeutics Cuts Workforce by 75% and Shifts Focus to Solid Tumor Program
investorshub.advfn.com ·
- TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors
Yahoo Finance ·
- Why Is Amgen (AMGN) Ending Its Crohn's Disease Research Partnership?
Yahoo Finance ·
- TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates
Yahoo Finance ·
- TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Yahoo Finance ·
- Prime Medicine, Inc. (PRME) Reports Q2 Loss, Misses Revenue Estimates
Yahoo Finance ·
- Cell and gene therapy manufacturers turn to specialist automation partners
pharmaceutical-technology.com ·
- TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies
Yahoo Finance ·
- TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Yahoo Finance ·
TScan Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $10.3M | $2.8M | $21.0M | $13.5M |
| Net income | -$129.8M | -$127.5M | -$89.2M | -$66.2M |
| Diluted EPS | $-1.00 | $-1.14 | $-1.36 | $-2.75 |
| Total assets (year end) | $228.8M | $371.1M | $272.1M | $199.1M |
| Cash and equivalents (year end) | $152.4M | $178.7M | $133.4M | $120.0M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About TScan Therapeutics, Inc.
- Ticker
- TCRX (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Waltham, MA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1783328
Frequently asked questions
What exchange is TScan Therapeutics, Inc. listed on?
TScan Therapeutics, Inc. trades on the Nasdaq under the ticker symbol TCRX.
What industry is TScan Therapeutics, Inc. in?
TScan Therapeutics, Inc. is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is TScan Therapeutics, Inc. headquartered?
TScan Therapeutics, Inc.'s business address on file with the SEC is in Waltham, MA.
When does TScan Therapeutics, Inc.'s fiscal year end?
TScan Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did TScan Therapeutics, Inc. report?
TScan Therapeutics, Inc. reported $10.3M in revenue for calendar year 2025, according to its SEC filings.